Macular Degeneration Risk and Your Genetics
By the ExomeDNA Research Team | Last reviewed May 29, 2026
This page contains general information only. For personal health decisions, consult a qualified clinician.
Age-related macular degeneration is a leading cause of irreversible central vision loss in adults over 50, and genetics account for a substantial share of why some people develop it and others do not. The complement immune system — a cascade of proteins that normally defends the eye against pathogens and clears cellular debris — plays a central role: when key regulators carry less-effective variants, the cascade can turn against the retinal pigment epithelium itself, damaging the tissue that supports sharp central vision. Below: how the science works, which genes are involved, and what research-backed steps can reduce the environmental load on a retina that may already carry inherited vulnerabilities.
What is macular degeneration risk?
Macular degeneration (AMD) is the progressive deterioration of the macula, the central zone of the retina responsible for detailed vision. Genetics shape lifetime risk meaningfully — the trait is one of the most heritable common eye conditions studied, with multiple replicated genome-wide signals.
Age-related macular degeneration presents in two forms. Dry AMD, the more common form, involves slow accumulation of yellowish deposits called drusen beneath the retinal pigment epithelium (RPE) and gradual RPE atrophy. Wet AMD involves abnormal blood-vessel growth (choroidal neovascularization) that leaks fluid and scars the central retina rapidly. Most people with wet AMD had pre-existing dry AMD; genetics influence both the likelihood of developing AMD and the probability of progressing to the more visually destructive wet form.
The macula contains approximately five million cone photoreceptors that require constant metabolic support from the RPE. The RPE, in turn, sits atop Bruch's membrane and the choroidal vascular bed. When complement regulation fails, the RPE becomes a target of the immune attack it normally deflects — a slow-motion friendly-fire process that can span decades before vision loss becomes noticeable.
The genetics behind macular degeneration risk
AMD genetics center on the complement immune pathway. The complement system is a cascade of ~30 proteins that tag cellular debris and pathogens for removal. Under normal conditions, regulatory proteins keep complement activation tightly controlled at the surface of healthy cells. When regulatory proteins carry reduced-function variants, unchecked complement activity can injure the very tissue it is meant to protect.
CFH (complement factor H) encodes the principal alternative-pathway regulator. CFH acts as a cofactor for complement factor I and directly inactivates C3b, the central complement opsonin. The CFH variant Y402H (rs1061170) is the single strongest common genetic signal in AMD research — individuals carrying two copies of the risk allele at this locus carry meaningfully elevated AMD associations compared to the general population. Without adequate CFH activity, C3b accumulates on the RPE cell surface.
CFI (complement factor I) is the serine protease that cleaves C3b and C4b into inactive fragments, permanently halting further complement amplification. CFI requires cofactors, including CFH and CD46, to function. CFI variants that reduce cleavage efficiency allow C3b to persist longer on RPE surfaces, extending downstream complement activation.
CD46 (also called membrane cofactor protein, MCP) is expressed directly on RPE cells and functions as the cell's intrinsic "do not attack me" signal to the complement system. CD46 binds C3b and C4b deposited on the cell surface and presents them to CFI for inactivation. Variants reducing CD46 surface expression or binding affinity leave RPE cells more vulnerable to complement-mediated injury — the cell's own defense mechanism is weakened from within.
C3 is the central effector of all complement pathways. C3 activation generates C3b fragments that coat cellular surfaces and C3a anaphylatoxins that promote inflammation. In the AMD context, C3 activation at Bruch's membrane produces inflammatory signals and seeds the terminal complement cascade.
C9 encodes the final polymerizing component of the membrane attack complex (MAC). Once C5 is cleaved, C5b combines with C6, C7, and C8, and C9 polymerizes into a ring-shaped pore (C5b-9) that inserts into the target membrane. MAC pores in RPE cell membranes cause calcium influx and cellular stress. With sufficient MAC density, RPE cells lyse — the cellular basis of geographic atrophy. C9 variants that affect polymerization rate or channel stability influence how much RPE damage occurs per complement activation event.
ARMS2 (age-related maculopathy susceptibility 2) encodes a small secreted protein localized to the choroidal extracellular matrix. ARMS2 is the second-largest genetic signal in AMD and acts independently of the complement loci. Its precise mechanism is still being characterized, but the 10q26 region harboring ARMS2 and the adjacent serine protease HTRA1 has been associated with AMD in multiple large cohorts. HTRA1 cleaves extracellular matrix proteins and modulates TGF-beta signaling in the choroid — changes that may affect the structural integrity of Bruch's membrane over time.
CETP (cholesterol ester transfer protein) introduces a lipid-metabolism angle. CETP transfers cholesterol esters from HDL to LDL and VLDL particles and is expressed in RPE cells. Drusen — the defining early lesion of AMD — contain cholesterol esters, apolipoproteins, and complement proteins in a lipid-rich deposit. CETP variants that alter cholesterol ester trafficking through the RPE may influence the lipid content of Bruch's membrane and the rate at which drusen accumulate.
PDGFB (platelet-derived growth factor B) is relevant primarily to the wet AMD subtype. PDGFB and its receptor PDGFRbeta recruit pericytes to nascent vessels and stabilize vascular walls. Aberrant PDGFB signaling has been linked to pathological choroidal neovascularization — the abnormal vessel growth that defines wet AMD and causes rapid central vision loss.
HERC2 is an E3 ubiquitin ligase adjacent to OCA2 in the pigmentation gene cluster. Eye pigmentation influences light scatter and the phototoxic load on the macula. HERC2 variants that affect pigmentation may modify AMD susceptibility through this photobiological pathway.
The complete complement cascade in AMD thus reads: CFH and CFI variants impair C3b inactivation → C3 activates at Bruch's membrane → C3b deposits on RPE → C5 convertase assembles → C5b triggers MAC assembly → C9 polymerizes into MAC pore → RPE cell lysis → geographic atrophy. CD46 variants compound this by weakening the RPE's intrinsic resistance at every step.
What the research says
Research base: Robust. AMD is one of the most thoroughly genetically characterized common diseases. Genome-wide association studies have identified more than 50 independent loci, and the complement pathway genes — CFH in particular — have been replicated across dozens of independent cohorts spanning hundreds of thousands of participants.
A 2024 large-scale study by Verma et al. (2024) examining genetic architecture across 2,068 traits in the VA Million Veteran Program, which included electronic health record phenotypes such as PheCode 362.2 (degeneration of macula and posterior pole of retina), confirmed robust genetic signal for macular degeneration in a large, diverse veteran population. The VA MVP cohort is one of the largest genomic biobanks in the world, providing replication power that extends well beyond traditional AMD-specific study populations (Verma et al. 2024).
The specific complement-gene findings summarized here have been replicated in independent studies including the AMD Gene Consortium and the International AMD Genomics Consortium. The CFH Y402H locus and the ARMS2/HTRA1 10q26 locus together account for the majority of the population-attributable genetic risk for AMD. C3 and CFI loci have been independently replicated at genome-wide significance (p < 5×10⁻⁸). The C9 and CD46 loci add to the complement-system genetic architecture and are consistent with the established biological model.
ClinVar documents pathogenic variants across CFH, CFI, CD46, C3, C9, CETP, HERC2, HTRA1, PDGFB, and ARMS2 in the context of multiple AMD subtypes — including Age related macular degeneration 4, 7, 9, 13, and 15 — reflecting the multi-gene architecture of a heterogeneous condition.
For the full statistical approach underlying ExomeDNA's genetic scoring for this trait, see our methodology page for details on how genome-wide association signals are integrated and weighted.
How macular degeneration risk affects you
AMD risk from genetics does not translate directly to a certainty of vision loss. The condition typically develops over decades, and environmental and behavioral inputs interact substantially with genetic predisposition.
The clinical course matters. Most AMD begins as early dry AMD — small drusen detected on dilated retinal examination, with no noticeable vision change. Some individuals progress to intermediate AMD (larger drusen, possible pigment changes). A subset progresses to advanced AMD, either geographic atrophy (loss of RPE cells causing a blind spot in central vision) or neovascular (wet) AMD. Progression is neither universal nor predictable from genetics alone.
Genetic risk from this profile is polygenic — it reflects the combined influence of multiple common variants, each with modest individual effect. No single variant in this gene set determines outcome. A higher genetic score reflects a population-level association, not a personal forecast.
Central vision is the vision used for reading, facial recognition, and driving. Early AMD typically does not impair peripheral vision. The functional impact becomes significant in advanced stages. In most health systems, the window for intervention — AREDS2 supplements for intermediate AMD, anti-VEGF injections for wet AMD — is well before advanced vision loss.
Working with your macular degeneration risk result
Genetic information about AMD risk is most useful as a motivator for the modifiable factors known to interact with complement-pathway biology and drusen formation. Research supports several specific actions.
Attend regular dilated eye examinations. For adults over 40 with AMD family history or elevated genetic risk, annual dilated exams allow drusen detection at the stage when intervention (AREDS2 supplements) has proven benefit. Early AMD detected on exam is the actionable window.
Do not smoke, and prioritize smoking cessation if you currently smoke. Smoking is the strongest established modifiable risk factor for AMD progression. Oxidative stress from cigarette smoke compounds complement-pathway dysfunction in the RPE and accelerates drusen formation. The association is dose-dependent and causally supported.
Consider an AREDS2 supplement regimen for individuals with intermediate AMD. The Age-Related Eye Disease Study 2 (AREDS2) demonstrated that a specific formulation — vitamin C, vitamin E, lutein, zeaxanthin, zinc, and copper — reduced progression from intermediate to advanced AMD by approximately 25% over five years. This benefit applies to intermediate AMD, not early AMD or primary prevention. Confirm staging with an ophthalmologist.
Adopt a Mediterranean-style dietary pattern. Diets high in leafy greens, oily fish, and colorful vegetables provide lutein, zeaxanthin, omega-3 fatty acids, and antioxidants that support macular pigment density and RPE metabolic health. Higher dietary intake of these nutrients is associated with lower AMD incidence in observational research.
Manage blood pressure and cardiovascular health. AMD shares vascular risk factors with cardiovascular disease. Hypertension impairs choroidal blood flow and increases oxidative stress in Bruch's membrane. Blood pressure control that is appropriate for cardiovascular health is also relevant to AMD risk management.
Limit UV exposure with UV-blocking eyewear. Cumulative ultraviolet light exposure increases photo-oxidative stress on the RPE. UV-blocking lenses reduce this environmental load, which is particularly relevant for those with the pigmentation-related HERC2 variants that may affect phototoxic susceptibility.
Know your family history and share it with your eye care provider. First-degree relatives of AMD-affected individuals carry elevated risk independent of genetic testing. A family history combined with genetic risk information gives the most complete picture for clinical screening planning.
Related traits and genes
Macular degeneration shares genetic architecture and biological pathways with several other traits in your ExomeDNA profile.
Sibling traits (Eye and Vision Aging category):
- Glaucoma Risk — another major age-related eye condition with complement-system and vascular components
- Cataract Risk — lens clouding that shares oxidative-stress and aging biology with AMD
- Diabetic Retinopathy Risk — retinal vascular disease where PDGFB-related pericyte biology overlaps with AMD neovascularization
Cross-category traits sharing gene pathways:
- HDL Cholesterol — CETP variants studied here also appear in lipid metabolism traits; cholesterol ester transport connects AMD biology to cardiovascular lipid profiles
- Inflammatory Response — the complement system is a branch of innate immunity; C3 and CFH variants implicated in AMD intersect with broader inflammatory phenotypes
Gene pages for CFH, ARMS2, C3, C9, CFI, CD46, CETP, HTRA1, HERC2, and PDGFB are not yet available in the ExomeDNA gene library; they will appear in a future update.
Frequently asked questions
Is AMD genetic? Yes, genetics play a substantial role. AMD is one of the most heritable common eye conditions — studies estimate that genetic factors account for 45–70% of AMD risk. The strongest genetic signals fall in the complement immune pathway, particularly the CFH and ARMS2/HTRA1 loci, which have been replicated in multiple large cohorts.
What does it mean if my genetic score for macular degeneration risk is elevated? An elevated score reflects a higher-than-average polygenic burden of AMD-associated variants compared to the general population. It does not mean AMD is certain or inevitable. Many people with elevated genetic risk never develop significant AMD, especially if they avoid smoking, maintain good cardiovascular health, and attend regular dilated eye examinations for early detection.
Can I do anything to lower my macular degeneration risk? You cannot change your genetic variants, but you can reduce the modifiable inputs that interact with complement-pathway biology. Not smoking is the single most impactful action. AREDS2 supplementation reduces progression risk in people with confirmed intermediate AMD. A Mediterranean-style diet, blood pressure management, UV-protective eyewear, and regular eye exams round out the evidence-supported strategy.
What is the complement system and why does it matter for AMD? The complement system is a branch of the immune system that tags cellular debris and pathogens for removal. In the eye, the complement cascade can damage the retinal pigment epithelium when regulatory proteins — encoded by CFH, CFI, and CD46 — carry less-effective variants. The end product of runaway complement activation is the membrane attack complex (MAC), assembled in part by C9, which punches holes in RPE cell membranes and causes the cell death underlying geographic atrophy.
What is the difference between dry AMD and wet AMD? Dry AMD is the more common form — slow accumulation of drusen beneath the retinal pigment epithelium and gradual atrophy. Wet AMD involves abnormal blood vessel growth (choroidal neovascularization) that leaks fluid and scars the macula rapidly. Most wet AMD cases develop in eyes with pre-existing dry AMD. The anti-VEGF injections used to treat wet AMD target the neovascularization process; they do not reverse existing geographic atrophy.
At what age should I start getting regular eye exams if I have elevated genetic risk? Most eye care guidelines recommend dilated exams starting at age 40 for adults with AMD family history or risk factors. With elevated genetic risk, discussing a personalized schedule with an ophthalmologist is appropriate. Early AMD detected on examination is the intervention window — AREDS2 supplements are proven beneficial at the intermediate stage, not earlier.
Wellness Information. ExomeDNA provides educational interpretation of genetic variants for general wellness purposes only. This is not a clinical genetic test. Consult a healthcare provider before making health decisions. See our methodology and test limitations for details.
References
- Verma A, et al. (2024). Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. PLOS Genetics. PMID: 39024449.
Data sources: GWAS Catalog; Open Targets Genetics (L2G v25); ClinGen; ClinVar; NCBI Gene.
This page is published by the ExomeDNA Research Team. Last reviewed: 2026-05-29.
ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.